Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01159652 · ClinicalTrials.gov registry record · Phase 4

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

A Phase 4 study of Sleep and Memory, sponsored by St. Luke's Hospital, Chesterfield, Missouri.

Completed
Registry status
Phase 4
Development phase
26
Enrollment target
1
Study location

NCT01159652: Completed Phase 4 study of Sleep and Memory, sponsored by St. Luke's Hospital, Chesterfield, Missouri.

NCT01159652 is a Phase 4 study of Sleep and Memory that has completed, run by St. Luke's Hospital, Chesterfield, Missouri. The registered enrollment target is 26 participants, below the 4,166-participant average among 151 other Sleep trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01159652, a Phase 4 study of Sleep and Memory, has completed, sponsored by St. Luke's Hospital, Chesterfield, Missouri.

COMPLETED
Registry status
Phase 4
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of two hypnotic medications, zolpidem extended release and zaleplon, on memory. It is expected that a hypnotic with shorter drug duration will allow greater memory consolidation than a hypnotic with longer drug duration.

Primary Outcome

Two memory tasks will be used to assess memory.

Conditions Studied

Interventions

  • DRUG zaleplon
  • DRUG zolpidem extended release
  • DRUG bedtime placebo
  • DRUG middle of the night placebo

Study Locations (1)

Missouri

  • St. Luke's Hospital Sleep Medicine and Research Center - Chesterfield

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2010-10
Est. Completion 2011-05
Phase Phase 4

What the finished NCT01159652 record still lists

NCT01159652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 4,166-participant average among 151 other Sleep trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Sleep appearing as the primary indexed condition, and to 4 interventions - of which zaleplon is the first listed.

NCT01159652 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT01159652 about?

NCT01159652 is a clinical study titled "Hypnotic Medications and Memory: Effect of Drug Exposure During the Night". The purpose of this study is to determine the effect of two hypnotic medications, zolpidem extended release and zaleplon, on memory. It is expected that a hypnotic with shorter drug duration will allow greater memory consolidation than a hypnotic with longer drug duration.

What is the current status of trial NCT01159652?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2010-10. Estimated completion is 2011-05.

What conditions does trial NCT01159652 study?

This clinical trial studies the following conditions: Sleep, Memory.

What interventions are being tested in trial NCT01159652?

The interventions under investigation include: zaleplon (DRUG), zolpidem extended release (DRUG), bedtime placebo (DRUG), middle of the night placebo (DRUG).

Who is sponsoring clinical trial NCT01159652?

This trial is sponsored by St. Luke's Hospital, Chesterfield, Missouri, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01159652 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01159652's enrollment target sits among peer trials

26 127th of 151 higher than 23 of 151 other Sleep trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01159652, the US trial registry maintained by the National Library of Medicine. NCT01159652 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.